NCT07342244

Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Study Summary

This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

Want to learn more about this trial?

Request More Info

Interventions

CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell TransplantationDRUG
CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation

Study Locations

FacilityCityStateCountry
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026